Radius Health is a commercial biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuroscience.
The Radius portfolio consists of commercial and clinical development assets, including mid to late-stage drug candidates.
We are dedicated to serving those patients suffering from bone loss and, in 2017, launched our first commercial product in the U.S. for post-menopausal women with osteoporosis at high risk for fracture.
The work of our Neuroscience group is centered around the clinical development of our investigational synthetic cannabidiol oral solution (RAD011), which has potential utilization in multiple orphan neurological disease areas. Our team is driven by the needs of those suffering from neurological diseases and seeks to expand its initiatives into other neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas.
In partnership with Menarini Group, our pipeline includes the investigational drug elacestrant being developed for the potential treatment of patients with ER+ HER2- breast cancer. In October 2021, the companies jointly announced positive topline results from the Phase 3 trial (EMERALD) evaluating elacestrant as a hormonal treatment for postmenopausal breast cancer.
